Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Patrick Harrison Carroll sold 23,287 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $34.31, for a total value of $798,976.97. Following the transaction, the insider now owns 209,661 shares in the company, valued at approximately $7,193,468.91. This trade represents a 10.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Hims & Hers Health Stock Performance
Shares of HIMS stock traded up $1.83 during trading hours on Friday, hitting $34.70. 14,141,140 shares of the company were exchanged, compared to its average volume of 13,653,104. Hims & Hers Health, Inc. has a fifty-two week low of $11.20 and a fifty-two week high of $72.98. The company has a 50 day simple moving average of $39.02 and a two-hundred day simple moving average of $28.55. The firm has a market cap of $7.71 billion, a P/E ratio of 78.69 and a beta of 1.37.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.
Institutional Trading of Hims & Hers Health
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Main Management ETF Advisors LLC acquired a new stake in Hims & Hers Health in the third quarter valued at approximately $672,000. Royce & Associates LP lifted its holdings in shares of Hims & Hers Health by 17.0% in the 3rd quarter. Royce & Associates LP now owns 341,000 shares of the company's stock worth $6,281,000 after purchasing an additional 49,500 shares in the last quarter. Blueshift Asset Management LLC grew its position in Hims & Hers Health by 834.8% in the 3rd quarter. Blueshift Asset Management LLC now owns 245,013 shares of the company's stock valued at $4,513,000 after purchasing an additional 218,804 shares during the period. Means Investment CO. Inc. grew its position in Hims & Hers Health by 23.5% in the 4th quarter. Means Investment CO. Inc. now owns 50,040 shares of the company's stock valued at $1,210,000 after purchasing an additional 9,508 shares during the period. Finally, Principal Financial Group Inc. increased its stake in Hims & Hers Health by 102.0% during the 3rd quarter. Principal Financial Group Inc. now owns 290,414 shares of the company's stock valued at $5,349,000 after purchasing an additional 146,621 shares in the last quarter. 63.52% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
HIMS has been the subject of a number of recent research reports. Leerink Partners boosted their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research report on Tuesday, February 25th. Truist Financial boosted their price objective on shares of Hims & Hers Health from $24.00 to $39.00 and gave the company a "hold" rating in a report on Wednesday, February 26th. Needham & Company LLC raised their target price on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a "buy" rating in a report on Tuesday, February 25th. Morgan Stanley downgraded shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and lifted their price target for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. Finally, Canaccord Genuity Group increased their price target on Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research report on Wednesday, February 19th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $37.31.
Read Our Latest Analysis on HIMS
About Hims & Hers Health
(
Get Free Report)
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Further Reading
Before you consider Hims & Hers Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.
While Hims & Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
